The Technical AnalystExchange: PNK Industry: Biotechnology
Rasna Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0173
America/New_York / 26 apr 2024 @ 12:28
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 13.35 mill |
| EPS: | -0.0100 |
| P/E: | -1.730 |
| Earnings Date: | Mar 30, 2023 |
| SharesOutstanding: | 771.81 mill |
| Avg Daily Volume: | 0.0002 mill |
| RATING 2024-04-26 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.730 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.730 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0002 (-101.36%) $-0.0175 |
| Date: 2024-05-01 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0163 - 0.0183 ( +/- 5.78%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0173 (0.00% ) |
| Volume | 0.0001 mill |
| Avg. Vol. | 0.0002 mill |
| % of Avg. Vol | 48.58 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RASP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RASP
Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. It focuses on developing small molecule drug candidates targeting NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma. The company is developing RASP-201 (LSD1), an enzyme that demethylates lysine side chain of histones; and RASP-301, an NPM1 gene that provides instructions for making nucleophosmin protein. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York.